Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05153408 · ClinicalTrials.gov registry record · Phase 1
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
A Phase 1 study, sponsored by Blueprint Medicines Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05153408 is a Phase 1 study that was terminated before completion, run by Blueprint Medicines Corporation. The registered enrollment target is 20 participants.
The verdict
NCT05153408, a Phase 1 study, was terminated before completion, sponsored by Blueprint Medicines Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.
Interventions
- DRUG osimertinib
- DRUG carboplatin
- DRUG pemetrexed
- DRUG BLU-701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2022-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05153408
The ClinicalTrials.gov registry entry for NCT05153408 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which osimertinib is the first listed.
NCT05153408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05153408 about?
NCT05153408 is a clinical study titled "(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC". This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.
What is the current status of trial NCT05153408?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-01-13. Estimated completion is 2022-12-09.
What interventions are being tested in trial NCT05153408?
The interventions under investigation include: osimertinib (DRUG), carboplatin (DRUG), pemetrexed (DRUG), BLU-701 (DRUG).
Who is sponsoring clinical trial NCT05153408?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.